Authors: Mohammad M. Hossain
At the beginning of Acquired Immunodeficiency Syndrome (AIDS) epidemic in the mid of 1981, a few hundreds of people were identified with human immunodeficiency virus type-1(HIV-1) infection and AIDS. The infected population increased to a total 7.3 million in 1990 and within 10 years, the rapid spread of infection reached an average of 28 million people in 2000, and was recently estimated at 36 million at the end of 2015. However, highly active antiretroviral therapy (HAART) in HIV-infected patient does not show signs and symptoms of AIDS and has shown to delay death among patient. There have been no declines in new HIV infection among adults and 1.9 million adults have become newly infected with HIV since 2010. A strategy to minimize the sexual transmission of HIV is to develop a topical microbicides alternative of vaccine. UC781 is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and which has significant anti-HIV-1 microbicidal activity. One of the concerns about the use of NNRTI as a microbicide is that they fail to prevent the transmission of NNRTI-resistant virus. In this study, HIV-1 resistant to UC781 varied with EFVR> UCR>NVPR>WT. These observations suggested that UC781 needs further clinical analysis for use in topical anti-HIV microbicide.
View/Download pdf